TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Idenix Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript Idenix Pharmaceuticals, Inc. (IDIX)Q1 2010 Earnings CallMay 3, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Bristol-Myers Squibb: Attractive, With a Couple Hiccups Jason Chew submits: With a 5% dividend, Bristol-Myers Squibb (BMY) provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero interest rate environment.There are however, a couple hiccups for investors to be aware of. Bristol is set to lose patent protection on its best-selling drugs, Plavix in 2011, and Avapro in 2012. Plavix and Avapro had sales of $6.1 and $1.3 billion, respectively in 2009, together accounting for about 39% of all revenue. Some of this revenue will be made up by growth from its portfolio of approved drugs. Abilify, already a $2.6 billion drug, increased sales 20% in 2009, the virology franchise of Baraclude, Reyataz, and Sustiva total another $3.4 billion in sales and grew about 10% in the period. Orencia and Sprycel are also doing well, albeit from smaller bases. Both products have the potential to reach over $1 billion in sales. Recently launched Onglyza, however, is off to a rather slow start. I estimate growth from these products can make up for approximately 40% of the revenue lost by Plavix and Avapro by 2013.Complete Story » seekingalpha.com |
Experts Urge Earlier AIDS Treatment Despite its notorious reputation, the virus that causes AIDS doesn't infect the human body easily, and the difficulties HIV has point to potential new prevention and treatment methods, according to a growing body of research. online.wsj.com |
ERT to Present at UBS Global Life Sciences Conference on September 20, 2010 [PR Newswire] - ERT , announced today that Dr. Michael J. McKelvey, the Company's President and CEO, and Keith Schneck, the Company's Executive Vice President and CFO, are scheduled to present at UBS Global Life Sciences Conference at 11:30 AM EDT on September 20, 2010 in New York City, New York. us.rd.yahoo.com |
Sanofi's Hostile Bid: Despite Problems, Genzyme Has Value Sanofi-Aventis (NYSE: SNY) said Monday that it has launched an $18.5 billion hostile offer for biotech company Genzyme (Nasdaq: GENZ), after it became fed-up with the Genzyme board's "unwillingness to engage" in discussions. The $69 per share offer is unchanged from the friendly proposal Sanofi-Aventis made privately to Genzyme's board of directors in July, which was promptly rejected publicly in August.Complete Story » seekingalpha.com |